Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.

[1]  M. Port,et al.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.

[2]  John R. Adams,et al.  Granulomatous reaction to titanium alloy: an unusual reaction to ear piercing. , 2006, Journal of the American Academy of Dermatology.

[3]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[4]  M. Pittelkow,et al.  Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. , 2006, Annals of internal medicine.

[5]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  M. Tweedle,et al.  Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.

[7]  H. Ersoy,et al.  Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium, and creatinine measurements , 2006, Journal of magnetic resonance imaging : JMRI.

[8]  R. Bucala,et al.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. , 2006, Seminars in arthritis and rheumatism.

[9]  S. Cowper.  Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  T. Ishiguchi,et al.  Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. , 2005, Radiation medicine.

[11]  B. Hamm,et al.  Contrast‐enhanced magnetic resonance angiography of the lower extremities: Standard‐dose vs. high‐dose gadodiamide injection , 2005, Journal of magnetic resonance imaging : JMRI.

[12]  Amin Fazeli,et al.  Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? , 2004, Archives of dermatology.

[13]  S. Cowper.  Nephrogenic fibrosing dermopathy: the first 6 years , 2003, Current opinion in rheumatology.

[14]  P. Leboit.  What nephrogenic fibrosing dermopathy might be. , 2003, Archives of dermatology.

[15]  B. Rogachev,et al.  Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  D. Cohen,et al.  Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). , 2003, Journal of the American Academy of Dermatology.

[17]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[18]  J. Adamson,et al.  NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  D. R. Hill.  X-Ray Measurements , 1975 .